// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Bioinformatical analysis of promotor interacting regions related to cardiovascular health and disease

Sanjay Goorwappa - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Vista

Pim kinase is a novel regulator of endothelium-driven thrombosis.

Eima Karim - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Coronary Artery Disease

AZD-1208

Investigation of the contribution of non-canonical inflammasome activation to LPS-induced foam cell formation in macrophages.

Kenechukwu Umerah - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Mechanisms underlying atrial dysfunction in heart failure: role of the mitochondrial permeability transition pore

Shiraz Khan - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

Digibind

Characterisation of in vivo and in vitro models for epigenomic investigations of cardiac hypertrophy

Diego Fernández-Aroca - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hypertrophic cardiomyopathy

Angiotensin II

Development of an in vitro model of ischemic stroke and reperfusion injury

Xenia Sawkulycz - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Ischemia-reperfusion injury

releasate

Revealing a roadmap for regenerative epicardium by comparing single-cell RNA sequencing of adult and fetal hearts

Vincent Knight-Schrijver - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Assessment of fluid status in porcine models of heart failure and pulmonary hypertension

Hamza Zafar - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

Esmolol

Characterising the role of platelets in the host immune response to invasive fungal infections

Amelia Drysdale - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Invasive fungal infection

N/A

Plasma membrane calcium atpase 4 regulates pro-inflammatory signalling in the pathophysiology of pulmonary artery endothelial cells

Ezra Leander David - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Cardiomyocyte-specific deletion of PMCA1 exacerbates cardiac inflammatory response

Alex Chelu - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Macrophage ATP8B1 is upregulated with age

Martha Clements - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Polycystin-1 suppresses apoptotic signalling in endothelial cells and protects from atherosclerosis

Jovana Serbanovic-Canic - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Flow-regulated EPAS1 limits atherosclerosis via metabolic control of endothelial proliferation

Siyu Tian - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hypercholesterolemia, Familial, 1

N/A

Proteomics of human heart failure: effects of mutations, medications and comorbidities

Javier Barallobre Barreiro - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

SERCA2a protein levels are unaltered in human heart failure

Isabella Ragone - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Dilated cardiomyopathy

Arginine hydrochloride

Senescent cardiomyocytes contribute to cardiac dysfunction following myocardial infarction

Rachael Redgrave - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Hypertrophic cardiomyopathy

Navitoclax

Defining the mirnome of vascular smooth muscle cells from patients with type 2 diabetes

Alisah Hussain - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

N/A

Comparing phenotypic characteristics of primary human smooth muscle cells isolated from distinct microvascular and macrovascular beds

Alisah Hussain - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Antibodies against oxidised low-density lipoprotein and valve calcification in the scot-heart trial

Adam Hartley - British Cardiovascular Society (BCS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Aortic valve calcification

N/A

Copyright © 2026. QuantiNova All rights reserved